<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: To evaluate the safety and effectiveness of triple therapy using insulin, <z:chebi fb="0" ids="6801">metformin</z:chebi>, and a thiazolidinedione following a course of dual therapy using insulin and <z:chebi fb="0" ids="6801">metformin</z:chebi> or insulin and a thiazolidinedione in type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>RESEARCH DESIGN AND METHODS: Twenty-eight type 2 diabetic subjects using insulin monotherapy (baseline HbA(lc) level 8.5%) who had been randomly assigned to insulin (INS) and <z:chebi fb="0" ids="6801">metformin</z:chebi> (MET) (INS + MET, n = 14) or INS and the thiazolidinedione <z:chebi fb="0" ids="9753">troglitazone</z:chebi> (TGZ) (INS + TGZ, n = 14) (dual therapy) for 4 months were given INS, MET, and TGZ (triple therapy: INS + MET, add TGZ; or INS + TGZ, add MET) for another 4 months </plain></SENT>
<SENT sid="2" pm="."><plain>The INS dose was not increased </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: HbA(1c) levels decreased in both groups during dual therapy and improved further during triple therapy (INS + MET 7.0 +/- 0.8, INS + TGZ 6.2 +/- 0.8, P &lt; 0.0001; INS + MET, add TGZ 6.1 +/- 0.4%, P &lt; 0.001; INS + TGZ, add MET 5.8 +/- 0.6%, P &lt; 0.05; and INS + TGZ vs. INS + MET, P = 0.02) </plain></SENT>
<SENT sid="4" pm="."><plain>Significant reductions in total daily insulin dose occurred in the INS + TGZ (-14.1 units, P &lt; 0.0001), INS + TGZ add MET (-13.7 units, P &lt; 0.01), and the INS + MET add TGZ groups (-17.3 units, P &lt; 0.003), but not in the INS + MET group (-3.2 units) (INS + TGZ vs. INS + MET P &lt; 0.05) </plain></SENT>
<SENT sid="5" pm="."><plain>Subjects in the INS + TGZ group experienced significant <z:mp ids='MP_0005456'>weight gain</z:mp> (4.4 +/- 2.7 kg, P &lt; 0.0005) </plain></SENT>
<SENT sid="6" pm="."><plain>No <z:mp ids='MP_0005456'>weight gain</z:mp> occurred in the INS + MET, INS + MET add TGZ, and INS + TGZ add MET groups </plain></SENT>
<SENT sid="7" pm="."><plain>CONCLUSIONS: Triple therapy using INS, MET, and TGZ resulted in lower HbA(lc) levels and total daily insulin dose than during dual therapy </plain></SENT>
<SENT sid="8" pm="."><plain>The use of triple therapy resulted in 100% of subjects achieving an HbA(lc) &lt;7.0%, while decreasing the dose of INS </plain></SENT>
<SENT sid="9" pm="."><plain><z:mp ids='MP_0005456'>Weight gain</z:mp> was avoided when MET therapy preceded the addition of TGZ therapy </plain></SENT>
<SENT sid="10" pm="."><plain>The addition of TGZ resulted in the greatest reductions in HbA(lc) levels and insulin dose </plain></SENT>
<SENT sid="11" pm="."><plain>Triple therapy using INS, MET, and a thiazolidinedione (such as TGZ) can be a safe and effective treatment in type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
</text></document>